Nat Commun:PPARγ的复发性激活变异与膀胱腔内肿瘤相关

2019-01-27 AlexYang MedSci原创

PPARγ/RXRα转录活性的上调是膀胱腔内肿瘤的一个关键事件。它能够使肿瘤细胞生长呈现出PPARγ依赖的模式,并且调控肿瘤微环境从而支持免疫监视逃逸。该信号通路的激活与PPARG增益/放大有关,并能够导致PPARγ的过表达和RXRα的复发激活点突变。最近,有研究人员指出,PPARγ的复发性变异能够激活PPARγ/RXRα途径,并产生PPARγ依赖的模式和支持PPARγ在膀胱腔内癌症中的关键作用。

PPARγ/RXRα转录活性的上调是膀胱腔内肿瘤的一个关键事件。它能够使肿瘤细胞生长呈现出PPARγ依赖的模式,并且调控肿瘤微环境从而支持免疫监视逃逸。该信号通路的激活与PPARG增益/放大有关,并能够导致PPARγ的过表达和RXRα的复发激活点突变。

最近,有研究人员指出,PPARγ的复发性变异能够激活PPARγ/RXRα途径,并产生PPARγ依赖的模式和支持PPARγ在膀胱腔内癌症中的关键作用。这些变异是通过蛋白质来发现的,包括N末端、DNA结合位点和配体结合区域,其中大多数能够增强蛋白活性。PPARγ变体中配体结合域变异的结构功能研究鉴定了获得功能的结构性元件。

最后,研究人员指出,他们的研究阐释了PPARG的基因组变异能够导致膀胱肿瘤腔内原癌基因PPARγ/RXRα途径的激活,这也许为治疗提供了其他的选择。

原始出处:

Natacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors. Nat Commun. 16 Jan 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909757, encodeId=0ab91909e5740, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Apr 04 13:39:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883556, encodeId=af51188355624, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 06 19:39:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087504, encodeId=be30208e50445, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 03 19:39:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342556, encodeId=9a291342556fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 29 09:39:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909757, encodeId=0ab91909e5740, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Apr 04 13:39:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883556, encodeId=af51188355624, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 06 19:39:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087504, encodeId=be30208e50445, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 03 19:39:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342556, encodeId=9a291342556fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 29 09:39:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-05-06 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909757, encodeId=0ab91909e5740, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Apr 04 13:39:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883556, encodeId=af51188355624, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 06 19:39:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087504, encodeId=be30208e50445, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 03 19:39:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342556, encodeId=9a291342556fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 29 09:39:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-12-03 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909757, encodeId=0ab91909e5740, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Apr 04 13:39:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883556, encodeId=af51188355624, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 06 19:39:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087504, encodeId=be30208e50445, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 03 19:39:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342556, encodeId=9a291342556fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 29 09:39:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]

相关资讯

湘雅专家戴“黑超”切膀胱瘤

3D技术已经进入了人们的日常生活,甚至步入了医院手术室。在3D高清腹腔镜的帮助下,屏幕上腹腔内的器官似乎变得触手可及,令术者们仿佛置身于3D影院一般。 12月30日,湘雅医院泌尿外科手术室就上演了这样一幕“3D大片”。由湘雅医院泌尿外科主任、湘雅名医齐琳教授领衔

2016 NCCN临床实践指南:膀胱肿瘤(Version2.2016)

英文标题:NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (Version 2. 2016)
简要介绍:2016年7月,美国国家综合癌症网络(NCCN)发布了膀胱肿瘤指南2016年第2版,指南更新摘要如下:
膀胱肿瘤:临床表现和初步实验室检查(BL-1)非肌层浸润性或Tis主要实验室检查或手术治疗(BL-1):1. 二次手